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Studies on the pathogenesis of cisplatin-Induced hypomagnesemia In
rats. After three weekly intraperitoneal injections of cisplatin (2.5 mg/kg
body wt), male Wistar rats developed chronic hypomagnesemia, which
was evident from the second week and persisted throughout the 8-week
experiments. Plasma magnesium concentration was 0.69 0.01 m in
cisplatin-treated rats compared to 0.80 0.02 m in pair-fed control
rats (P < 0.01) in the eighth week of experimentation. Despite a similar
dietary magnesium intake, urinary excretion of magnesium in cisplatin-
treated rats was inappropriately high, relative to the lower plasma
magnesium concentration, indicating the presence of renal magnesium
wasting induced by cisplatin. During the 3 weeks of cisplatin injections,
metabolic balance studies indicated abnormal renal excretion and a
reduction in the fractional intestinal absorption of magnesium. A
compensatory period of significantly greater retention of magnesium
then occurred in cisplatin-treated rats beginning in the fourth week.
Clearance and recollection micropuncture studies in a separate group of
rats revealed normal magnesium and calcium transport in the superficial
proximal and distal nephron. Following acute MgC12 infusion, the
urinary excretion of magnesium and calcium were significantly higher in
cisplatin-treated rats than in control rats; however, micropuncture
studies of superficial nephrons failed to demonstrate abnormal transport
of these divalent cations. It is possible, therefore, that 7 weeks of
cisplatin treatment led to tubular adaptation that might have obscured
the defect in magnesium reabsorption. Morphological examination
indicated that pathological changes were confined to the S3 segment of
proximal corticomedullary nephrons. Analysis of mineral content in the
bone and muscle at the end of the eighth week indicated a significant
reduction in bone magnesium and in bone and muscle phosphorus
content in cisplatin-treated rats compared with control rats. These
studies suggest that (1) abnormalities of magnesium metabolism were
present during cisplatin administration and involved both kidney and
intestine. (2) Abnormal renal magnesium transport persisted, along with
residual lesions in the S3 segment of corticomedullary nephrons. (3) The
chronic hypomagnesemia in this animal model is associated with a
significant decrease in body magnesium and phosphorus stores.
Etudes sur Ia pathogénie de l'hypomagnesemie induite par le cisplatine
chez le rat. Après 3 injections intraperitoneales hebdomadaire de
cisplatine (2,5 mg/kg), des rats males Wistar ont dCveloppC une
hypomagnesemie chronique qui Ctait Cvidente a partir de Ia deuxiCme
semalne et a persisté tout au long des 8 semaines d'expérimentation. La
concentration plasmatique en magnesium était de 0,69 0,01 mmole
chez les rats traités par le cisplatine et de 0,80 0,02 mmole chez les
rats contrOles nourris de facon identique (P < 0,01) a la huitième
semaine de l'experimentation. En depit d'apports alimentaires en
magnesium identiques, l'excrétion urinaire de magnesium chez les rats
traités par le cisplatine était élevée de facon inappropriée aux basses
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concentrations plasmatiques en magnesium, indiquant l'existence d'une
fuite rénale de magnesium provoquee par le cisplatine. Pendant les 3
semaines oü le cisplatine a Cté injectC, les etudes de Ia balance
métabolique ont montrC une excretion rénale anormale et une diminu-
tion de l'absorption fractionnelle intestinale du magnesium. Une
periode compensatoire de retention significativement plus grande du
magnesium est apparue ensuite chez les rats traités par le cisplatine, a
partir de la 4éme semaine. Les etudes de clearance et de microponction
faites dans un groupe séparé de rats a montré un transport normal du
magnesium et du calcium dans les portions superficielles proximales et
distales du nephron. AprCs une perfusion de MgCl2, l'excrétion urinaire
du magnesium et du calcium était significativement plus haute chez les
rats traités par le cisplatine que chez les rats contrôles; cependant les
etudes en microponction des nCphrons superficiels n'ont pas montrC
d'anomalies du transport de ces cations divalents. Ii est toutefois
possible que 7 semaines de traitement par Ic cisplatine conduisent a une
adaptation tubulaire qui peut avoir cache le dCfaut de reabsorption du
magnesium. L'examen morphologique a montré que les modifications
anatomopathologiques étaient limitées au segment S3 des nephrons
proximaux corticomédullaires. L'analyse du contenu mineral dans l'os
et Ic muscle a la fin de la 8Cme semaine a montrC une reduction
significative du contenu osseux en magnesium et en phosphore et du
contenu musculaire en phosphore chez les rats traitCs par le cisplatine,
par rapport aux rats contrôles. Ces etudes suggérent que 1) des
anomalies du métabolisme du magnesium sont survenues pendant
l'administration de cisplatine, atteignant les deux reins et I'intestin. 2)
Le transport renal anormal du magnesium a persisteé, ainsi que des
lesions rCsiduelles dans le segment S3 des nephrons corticaux
medullaires. 3) L'hypomagnesemie chronique dans ce modèle animal
est associée avec une diminution significative des reserves corporelles
en magnesium et en phosphore.
Cisplatin (cis-dichloro-diammine platinum), an inorganic plat-
inum compound, is an effective antineoplastic agent against
solid tumors [1, 2]. Various nephrotoxic effects associated with
cisplatin administration have been reported, including acute
and chronic renal failure [3, 4], impaired water metabolism [5,
6] and chronic hypomagnesemia [7, 81. Among the nephrotoxic
effects of cisplatin, hypomagnesemia has emerged as a partic-
ularly common problem; seventy-six percent of patients be-
came hypomagnesemic during cisplatin chemotherapy, and of
these, 50 percent remained persistently hypomagnesemic for as
long as 3 years following discontinuation of cisplatin treatment
[8]. This disorder may occasionally be accompanied by
hypokalemia and hypocalcemia and may vary in severity from
no symptoms to frank tetany. Information is limited regarding
the pathogenesis and mechanism of chronic hypomagnesemia in
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this disorder. In the present studies, we have produced an
animal model of cisplatin-induced hypomagnesemia in the rat
and utilized this animal model for the investigation of the
pathogenesis of hypomagnesemia. Specifically, we examined
the long-term effects of multiple low-dose cisplatin (2.5 mg/kg
body wt once weekly, x 3) on plasma electrolyte concentration,
renal function, external magnesium balance, and on the renal
tubular handling of magnesium, calcium, and phosphorus by
recollection micropuncture techniques. Morphologic changes
were correlated with the physiologic findings. Bone and muscle
mineral content were examined to assess the body stores of
minerals, particularly magnesium, in this animal model.
Methods
Male Wistar rats weighing 200 to 225 g were studied in
metabolic cages (Holtage Co., Cincinnati, Ohio, USA), which
allowed quantitation of food intake and separation of urine and
feces. All animals were fed a diet containing magnesium 0.03
g% (as MgSO4), calcium 0.41 g% (as CaCO3), phosphorus 0.3
g% (as K2HPO4), and distilled water ad libitum throughout the
experiments. After readjustment to the new environment in
metabolic cages for 7 days, animals were randomly divided into
two groups. Experimental animals were injected intraperitone-
ally wih 2.5 mg/kg body wt of cisplatin (Bristol Laboratories of
Canada, Ontario, Canada) every week for 3 weeks. In the
balance studies, the control animals were pair-fed, and were
injected in a similar manner with an equivalent volume of the
sterile 0.9% saline solution that served as the diluent for
cisplatin.
Balance cage studies
In these studies, 24-hr food intake, together with urinary and
fecal excretion, were measured daily for 1 week prior to
cisplatin administration (the baseline week) and during the first,
second, and third week of cisplatin injections in both cisplatin-
treated rats (N = 16) and in control rats (N = 12). During the
fourth and eighth week of experiments, 24-hr urines were
collected once every week, and feces were collected daily.
Free-flowing tail vein blood was collected from each rat once
weekly from the baseline week until the eighth week (during the
3 weeks of cisplatin administration, blood samples were col-
lected 24 hr after cisplatin injection). Blood samples and 24-hr
urine collections were analyzed for creatinine, sodium, potas-
sium, magnesium, calcium, and phosphorus. Endogenous cre-
atinine clearance and fractional urinary excretion of filtered
electrolytes were calculated by standard equations. Four-day
pooled collections of feces were used for analysis. Feces were
weighed, dried at 105°C for 48 hr, and ashed in a muffle furnace
for 24 hr at 650°C. The ashed feces were dissolved in nitric acid,
and the resulting solution was analyzed for magnesium.
Clearance and micropuncture studies
Two-phase clearance and recollection micropuncture exper-
iments were done in additional groups of cisplatin-treated (N =
12) and control (N = 8) rats during the seventh to eighth week
of experimentation (not pair-fed). mactin (Promonta, Hamburg,
West Germany) 100 mg/kg body wt administered intraperitone-
ally was used for anesthesia. the animals were placed on a
heated table to maintain body temperature at 37°C. After
tracheostomy, thyroparathyroidectomy was performed by
electrocautery, and the jugular vein, carotid artery, and bladder
were cannulated with polyethylene tubing. The left kidney was
then exposed by a subcostal incision and prepared for micro-
puncture by removal of surrounding fat and connective tissue,
then the kidney was immobilized in situ in a glass dish. The
kidney capsule was then removed and the exposed surface
covered with agar. When the agar hardened, a small area on the
top surface of the kidney was uncovered and bathed with 38°C
mineral oil. The kidney surface was illuminated with a fiber
optic light, and late proximal as well as early and late distal
puncture sites were identified by intratubule injections of lis-
samine green (10 to 20 nI of a 1% solution). Replacement of
surgical fluid losses with Ringer's solution (1 mIIlOO g body wt)
was followed by an infusion of Ringer's solution with 2% inulin
at a rate of 60 dIminute. After the equilibration period of 60
mm, two-phase experiments were commenced.
Phase 1
Urine was collected over 2 15-mm periods, and a midpoint
arterial blood sample (200 pi) was taken. Proximal and distal
tubular fluid samples were collected during this period.
Phase II
A prime of 0.25 ml of 150 mr.x MgCl2 was given, followed by
40 mri MgC12 balanced with 2% inulin in normal saline solution
at the rate of 60 pilmin. After an equilibration period of 60 mm,
urinary clearances and recollection micropuncture sampling of
proximal and distal tubule fluid were performed.
Bone and muscle mineral content
A separate group of animals (cisplatin-treated rats, N = 12;
control rats, N = 12) (not pair-fed) were treated similarly as
described above in metabolic cages. These animals were sacri-
ficed at the eighth week of experiments, when the dorsal
paraspinal muscle was removed, dried at 105°C for 48 hr, and
then defatted with ether. The fat-free dry sample was ashed at
650°C for 24 hr in a muffle furnace. The tibia was removed and
completely cleaned of soft tissues. After the shaft of the tibia
was split longitudinally and the bone marrow was removed, the
sample of bone was treated like muscle as described above. The
ash of both muscle and bone was then weighed and prepared for
analysis of magnesium, calcium, phosphorus, and potassium
content.
Morphological studies
Morphological examination of the kidney was carried out in a
group of four animals in both cisplatin-treated rats and control
rats at the following times: 24 hr after the first injection of
cisplatin, 24 hr after the second injection of cisplatin, and 48 hr,
1 week, and 4 weeks after the third injection of cisplatin. The
animals were anesthetized with mactin 100 mg/kg body wt, the
left kidney was fixed in vivo by the intra-arterial perfusion
method [9] with 4% formalin and 1% glutaraldehyde in phos-
phate-buffered saline (Sorensen's solution; pH 7.2, 200
mOsm/liter) at a pressure of 160 to 180 mm Hg. The fixed
kidney was transversely sectioned at about 2 mm intervals
immediately after harvesting. Two to three slices were fixed (in
the same fixative used for perfusion) for 24 hr in the cold. These
slices were then embedded in paraffin, sectioned at 3 microns,
and stained with hematoxylin-eosin (H and E) and periodic
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Table 1. Weight, plasma composition, renal function, and electrolyte excretions during 8 weeks of balance studies
Baseline
Week
1 2 3 4 5 6 7 8
Body wt, gC 213 2 239 3 245 4 240 4 270 5 281 5 304 4 322 5 331 6
CIS 214 2 238 2 249 3 266 4 277 4 290 4 310 9 335 10 353 9
Ccr, mi/mm
C 1.17 0.03 1.25 0.06 1.20 0.03 1.15 0.04 1.50 0.06 1.60 0.07 1.59 0.07 1.88 0.05 1.73 0.08CIS 1.16 0.03 1.27 0,06 1.24 0.06 1.17 0.08 1.29 0.08a 1.33 O.08a 1.38 0.O6 1.53 0.09a 1.63 0.09
PCa, mM
C 2.63 0.02 2.60 0.02 2.64 0.01 2.57 0.01 2.57 0.01 2.57 0.01 2.64 0.02 2.60 0.02 2.62 0.02CIS 2.63 0.02 2.59 0.02 2.62 0.02 2.57 0.01 2.57 0.02 2.60 0.02 2.60 0.04 2.61 0.02 2.65 0.02FE, %
C 0.52 0.06 0.62 0.09 0.48 0.07 0.40 0.04 0.82 0.12 0.80 0.07 0.81 0.16 0.69 0.15 0.63 0.16CIS 0.53 0.06 0.65 0.10 0.43 0.04 0.39 0.06 0.92 0.14 0.89 0.11 0.83 0.13 0.67 0.14 0.67 0.18
Px, mM
C 5.2 ±0.1 5.3 ±0.1 5.1 ±0.1 5.3 0.1
0.1 5.2 0.1 5.3 0.1 0.1 0.1 5.7 0.l 5.4 0.2
FEK, %
C 4.4 4.7 6.0 6.0 5.1 5.1 ±0.3 5.7 0.4 6.1CIS 4.7 0.7 5.4 0.5 6.9 0.4 7.4 0.6k 7.7 0.5a 7.8 0.9 6.5 0.4 6.5 0.4 6.7 0.6
PPi, %
C 2.61 0.04 2.34 0.03 2.15 0.02 2.29 0.04 2.34 0.05 2.22 0.08 2.28 0.03 2.27 0.03 2.10 0.01CIS 2.59 0.03 2.32 0.12 2.37 0.04 2.23 0.04 2.32 0.03 2.22 0.03 2.27 0.03 2.29 0.03 2.24 0.O3'
FE1, %C 12±1 16±1 15±1 13±1 11 16±1 15±1 13±1 12±1
CIS 12 1 16 1 15 1 17 ia 13 1 16 1 16 1 13 1 12 1
Values are means SEM for 12 control rats (C) and 16 cisplatin-treated rats (CIS, received cisplatin injection 2.5 mg/kg body wt i.p. q weekly
at 1st, 2nd, 3rd weeks.
Abbreviations are: Cçr, creatinine clearance; PCa, plasma calcium concentration; PK, plasma potassium concentration; plasma phosphorus
concentration; FE, fractional urinary excretion of filtered load.
ap< 0.01; bp< 0.05.
acid-Schiff solution. A small piece of kidney containing cortex
and medulla was similarly fixed, but embedded in polyglycol
methacrylate (Polysciences Inc., Warrington, Pennsylvania,
USA), sectioned at about 1 micron, and stained with H and E.
From each harvested kidney, a small block of tissue from the
corticomedullary junction and the superficial cortex was ob-
tained for electron microscopic studies. These blocks of tissue
were diced into 1 mm3 bits, fixed in the same solution used for
perfusion, and embedded in Epon-Araldite (Polysciences Inc.).
Thin sections were stained with toluidine blue and examined
with a light microscope. From blocks containing the outer stripe
of the medulla, ultrathin sections were cut with diamond
knives, stained with lead citrate and uranyl-acetate, and exam-
ined with a Zeiss EM 109 electron microscope (Carl Zeiss,
Oberkochen, West Germany).
Analytical methods
Sodium and potassium were analyzed by a flame photometer
(Corning 450, Medfield, Massachusetts, USA), calcium and
magnesium by atomic absorption spectrophotometer (Jarrell-
Ash 850, Pittsburgh, Pennsylvania, USA), and phosphorus by a
standard colonmetric method. Plasma and urinary creatinine
was determined by a VP Abbott spectrophotometer (Abbot
Laboratories, Dallas, Texas, USA). Urinary inulin concentra-
tion was determined by the method of Fuhr, Kaczmarczyk, and
Kruttgen [10], and plasma and tubular fluid inulin concentration
were measured by the microfluorometric method of Vurek and
Pegram [11]. Tubular fluid electrolyte concentrations were
measured by a Camebax electron microprobe (Cameca Instru-
ments, Inc., Stamford, Connecticut, USA). Plasma ultrafilter-
able magnesium and calcium were determined by Amicon
Centriflo ultrafiltration cones (Amicon Corp., Lexington, Mas-
sachusetts, USA) in a separate group of normal rats (N = 10)
and in cisplatin-treated rats at the second week of cisplatin
injection (N = 6), and at the eighth week of experimentation (N
= 6). There was no significant difference in the ultrafilterable
fraction of plasma magnesium and calcium in these three groups
of rats. (Plasma ultrafilterable magnesium = 76% of total
plasma magnesium concentration; plasma ultrafilterable cal-
cium = 64% of plasma calcium concentration).
The Student's ttest, paired or unpaired as appropriate, was
used for the statistical analysis.
Results
Plasma composition, renal function, and electrolyte
excretions
Mean values for body wt, plasma electrolyte concentrations,
renal function, and urinary electrolyte excretions of cisplatin-
treated rats and (pair-fed) control rats are shown in Table 1. The
glomerular filtration rate (GFR) as judged by endogenous cre-
atinine clearance was the same in both groups during the
baseline week. After the third cisplatin injection and in the
fourth week, GFR was significantly lower in cisplatin-treated
than in control rats. There was no mortality associated with the
cisplatin administration in these experiments. Plasma calcium
concentration and fractional urinary excretion of filtered cal-
cium were similar in both groups throughout the experiments. A
slight but significant increase in fractional urinary excretion of
potassium in cisplatin-treated rats occurred on the third and the
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Table 2. Magnesium and sodium excretions during 8 weeks of balance studies
Baseline
Week
1 2 3 4 5 6 7 8
V, mi/mm
C 0.014 0.010 0.011 0.016 0.012 0.013 0.013 0.012 0.008
0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
CIS 0.009a 0.011 0.012 0.015 0.014 0.015 0.015 0.014 0.016a
0.001 0.001 0.001 0.002 0.001 0.001 0.001 0.001 0.002
FENa, %
C 1.23 0.95 0.97 0.95 1.20 1.08 1.18 1.06 0.89
0.04 0.02 0.03 0.03 0.04 0.06 0.06 0.04 0.07
CIS 1.20 l.04' 0.82a 0.65a 1.09 1.20 1.16 1.14 0.94
0.04 0.04 0.04 0.08 0.06 0.09 0.06 0.06 0.06
PMg, M
C 0.79 0.76 0.79 0.76 0.79 0.81 0.82 0.80 0.82
0.01 0.02 0.01 0.01 0.01 0.01 0.03 0.02 0.03
CIS 0.78 0.73 0.67a 0.64a 0.78a 0.72a 0.71k 0.69a 0.69a
0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02
FEMg, %
C 2.87 3.79 3.79 3.06 2.59 3.46 3.21 3.56 2.88
0.32 0.45 0.14 0.17 0.26 0.32 0.20 0.19 0.22
CIS 3.14 3.24 4.19 3.19 4.42a 3.56 4.62a 2.84 3.17
0.31 0.46 0.35 0.16 0.37 0.35 0.38 0.84 0.79
Values are SEM. Numbers of rats and type of treatment same as Table 1.
Abbreviations are: V, urinary volume; FENa, fractional urinary excretion of sodium; PMg, plasma magnesium concentration; FeM8, fractional
urinary excretion of magnesium.
fourth week of experiments (Table 1). There was no significant
difference between groups in the fractional urinary excretion of
phosphorus (Table 1).
The effect of cisplatin on the plasma magnesium concentra-
tion is shown in Table 2. During the baseline period, plasma
magnesium concentration was similar in cisplatin-treated and
control rats (0.79 0.01 and 0.78 0.01 m, respectively).
After the third injection of cisplatin in the third week, cisplatin-
treated rats developed significant hypomagnesemia (plasma
magnesium concentration 0.64 0.02 m in cisplatin-treated
rats and 0.79 0.01 m in control rats, P < 0.01). The
hypomagnesemia persisted throughout the eight weeks of the
experiments. Despite a significantly lower plasma magnesium
concentration, fractional urinary excretion of filtered magne-
sium was similar in both groups throughout the experiments
(Table 2).
Metabolic balance studies
Magnesium balance
The data on magnesium balance data are shown in Table 3.
The average daily dietary magnesium intake, urinary magne-
sium excretion, fecal magnesium excretion, fractional gastroin-
testinal magnesium absorption, and the overall positive magne-
sium balance were similar during the baseline week. During the
3 weeks of cisplatin injections, the daily food intake and hence
the amount of magnesium consumed per day were similar in the
cisplatin-treated rats and control rats due to pair-feeding. Daily
urinary and fecal excretion of magnesium were similar in the
two groups during the first and second week; however, in the
third week, the daily fecal excretion of magnesium was signif-
icantly higher in cisplatin-treated than in control rats (42 7 vs.
31 2, respectively, P < 0.05). Moreover, the fractional
gastrointestinal magnesium absorption was significantly lower
in cisplatin-treated rats during all three weeks of cisplatin
administration. The failure of the gastrointestinal tract to ab-
sorb magnesium normally despite a lower dietary intake of
magnesium resulted in a significantly less positive magnesium
balance of 30 9 vs. 53 3 tmoles/day in cisplatin-treated and
control rats, respectively (P < 0.01). A compensatory period of
significantly more positive magnesium balance occurred in
cisplatin-treated rats between the fourth and eighth week.
Fractional gastrointestinal magnesium absorption was signifi-
cantly higher and fecal magnesium excretion significantly lower
in cisplatin-treated rats compared to control rats from the fourth
week through the sixth week. However, the absolute and
fractional urinary magnesium excretion were similar in the two
groups during these periods.
Clearance and micropuncture data
Table 4 shows the mean clearance data obtained during the
micropuncture experiments in 12 cisplatin-treated and eight
control rats following acute thyroparathyroidectomy during the
seventh and eighth week. The whole kidney GFR as measured
by inulin clearance was not significantly different between these
two groups. The fractional urinary sodium excretion was not
different during phase I and phase II. The plasma magnesium
concentration was significantly lower in cisplatin-treated than in
normal rats (0.64 0.01 vs. 0.76 0.02 mM, respectively, P <
0.01), but fractional urinary magnesium excretion was not
significantly different. Although these control rats were not
pair-fed, the data are similar to those derived from the 24-hr
clearance and balance studies in which pair-feeding was em-
ployed, and indicate that renal magnesium wasting was again
present in cisplatin-treated rats. During phase I, fractional
urinary calcium excretion was also similar in the two groups.
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Table 3. Results of magnesium balance studies
Week
Baseline 1 2 3 4 5 6 7 8
Mg intake,
pmolesIday
C 185±1 158±2 133±2 119±1 210±5 200±5 192±4 198±6 194±6
CIS 184±5 180±7 154±9a 1009b 220±6 215÷6b 212÷4b 2145b 2154b
Urinary Mg excretion,
pmo1es/day
C 28±3 64±1 44±2 35±2 41±3 45±3 45±3 42±4 41±2
CIS 29±3 33±6 39±4 27±la 45±4 47±3 47±3 45±3 43±5
Fecal Mg excretion,
mo1es/day
C 49±3 33±3 34±3 31±2 66±4 78±7 79±6 79±5 76±5
CIS 48±2 56±3 59±4 42±71 533b 634b 614b 72±3 72±3
Fractional gastrointes-
tinal Mg absorption,
%
C 74±1 79±2 74±2 74±2 69±2 61±2 59±3 60±2 61±2
CIS 74 1 69 2b 62 3b 58 3 76 2' 69 2 71 2 67 ia 66 1b
Positive Mg balance,
/.Lmo!es/day
C 108±8 61±2 55±3 53±3 102±4 77±5 68±5 77±7 77±9
CIS 108 6 92 9 57 9 30 9 122 5 105 9b 104 4 97 7b 100 6b
Values are means SEM.
a P < 0.01; b p < 005
Numbers of rats and type of treatment same as Table 1.
Table 4. Plasma electrolyte composition and clearance data of micropuncture expenmentsa
Cm FENa PMg FEMS FEca
mi/mm % mri % %
Phase I control
C (N = 8) 1.54 0.29 0.10 0.04 0.76 0.02 5.07 1.31 0.30 0.07
CIS (N = 12) 1.46 0.17 0.09 0.01 0.64 0.OIa 6.16 1.33 0.31 0.13
Phase II MgC12 infusion
C (N = 8) 1.46 0.17 0.32 0.06 2.10 0.07 54.0 4.1 2.77 0.47
CIS (N = 12) 1.45 0.09 0.36 0.04 2.08 0.06 70.5 4.Oa 5.36 0.55
All micropuncture experiments were performed during the seventh and eighth weeks,
Values are means SEM.
Abbreviations and animal parameters same as in Tables 1 and 2 except where noted.
Abbreviation: C1,,, inulin clearance.
a P < 0.01.
Upon MgC12 infusion in phase II, plasma magnesium concen-
tration rose to similar levels (2.08 0.06 m in cisplatin-treated
rats vs. 2.10 0.07 m in control rats). However, a signifi-
cantly higher fractional urinary excretion of magnesium was
noted in cisplatin-treated than in normal rats (70.5 4.0% vs.
54.0 4.1%, respectively, P < 0.01), again indicating renal
magnesium wasting. During MgC12 infusion, a significantly
higher fractional urinary calcium excretion was also noted in
cisplatin-treated than normal rats (5.36 0.55% vs. 2.77
0.4%, respectively, P < 0.01).
Micropuncture data during the control phase (phase I) and
MgC12 infusion (phase II) are given in Table 5. There were no
significant differences in proximal and distal (TF/P)1, (TF/P)Na,
(TFIP)ca, and (TF/P)Mg between treated and control rats in
either phase. Figure 1 demonstrates the fraction of filtered
magnesium remaining at various sites in the superficial nephron
during MgCl2 infusion (phase II). The fraction of ifitered mag-
nesium remaining in the proximal and distal tubule was not
significantly different between the groups. However, a signifi-
cantly higher fractional urinary magnesium excretion was noted
in cisplatin-treated rats than in control rats (70.5 4.0% vs.
54.0 4.1%, respectively, P < 0.01). Similarly, the fraction of
filtered calcium remaining in the proximal and distal tubules
were not different in cisplatin-treated and control rats, but
fractional urinary calcium excretion was higher in cisplatin-
treated than normal rats (5.36 0.55% vs. 2.77 0.47%,
respectively, P < 0.01).
Bone and muscle mineral content
The mineral composition of bone and muscle, expressed as
percentage of ash wt, are shown in Figure 2. Bone magnesium,
potassium, and phosphorus were significantly decreased in
cisplatin-treated rats compared to control rats (bone magnesium
content 0.65 0.01% vs. 0.52 0.01%, respectively, bone
potassium content 0.25 0.02% in cisplatin-treated rats vs.
0.17 0.01% in control rats; bone phosphorus content 9.17 ±
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Table 5. Proximal and distal micropuncture data
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Mean proximal Mean distal
(TF/P)1 (TF/P)Na (TF/UF)Mg (TF/UF)ca (TF/P)1 (TFIP)Na (TF/UF)Mg (TF/UF)ca
Phase I control
C (N = 8)
CIS (N = 12)
Phase II MgCI2
infusion
C (N = 8)
CIS (N = 12)
2.91 0.25
3.02 0.23
1.96 0.17
2.19 0.21
0.96 0.03
1.02 0.02
1.00 0.02
1.03 0.03
2.42 0.19
2.58 0.19
1.82 0.10
1.99 0.19
1.13 0.04
1.20 0.03
1.34 0.04
1.35 0.04
11.63 0.98
12.76 0.92
9.92 0.89
8.98 0.93
0.29 0.03
0.26 0.04
0.25 0.06
0.34 0.07
0.23 0.04
0.29 0.06
3.52 0.41
3.61 0.39
0.30 0.05
0.36 0.05
0.39 0.08
0.47 0.09
Values are means SEM.
Abbreviations are: (TF/P)1, tubular fluid and plasma concentration ratio of inulin; (TF/P)Na, tubular fluid and plasma concentration ratio of
sodium; (TF/UF)MS, tubular fluid and ultrafilterable concentration ratio of magnesium; (TF/UF)a, tubular fluid and ultrafilterable concentration
ratio of calcium.
0
Fig. 1. Fraction of the filtered magnesium remaining at the proximal
and distal micropuncture sites in control (—•) rats (N =8) and
cisplatin-treated (O----O) rats (N = 12) during MgCI2 infusion. Data are
expressed as means SEM. < 0.02
% % %
LI ri [1
Mg
Fig. 2. Bone and muscle mineral content in control ()rats (N = 12)
and cisplatin-treated () rats (N = 12) at the end of the eighth week.
Data are expressed as means SE of mg% of fat-free dried ash wt.
<0.01
Fig. 3. Outer stripe of medulla of the kidney from the cisplatin-treated
rat 24 hr after the second cisplatin injection. Cellular debris is present
in the lumens of several tubules, a number of which are lined by flat
epithelial cells devoid of brush borders. Compare these tubules with the
normal-appearing proximal tubules in the lower right corner of the
figure. (H and C, x250)
control rats. Muscle calcium, magnesium, and potassium con-
tent were similar in both groups. However, muscle phosphorus
content was significantly decreased in cisplatin-treated rats
(4.40 0.21% vs. 6.01 0.29%, respectively, P < 0.01).
Morphological studies of the kidney
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0.11% vs. 8.02 0.19%, respectively, P < 0.01). Bone calcium
content was not significantly different in cisplatin-treated and
Significant changes were noted in the outer stripe only.
Except for some cytoplasmic rarefaction and an increased
number of vesicles in very occasional cells of the outer stripe S3
segment (according to the criteria of Maunsbach [121), no
morphological changes were noted in cisplatin-treated rats 1
day after the first cisplatin injection. Patchy necrosis of cells of
S3 segments in the outer stripe was noted I day after the second
cisplatin injection (Fig. 3). Cellular debris was present in some
tubular lumens in the outer stripe. A number of tubules in this
region were somewhat dilated and lined by flattened epithelium
that was characterized ultrastructurally by having short, stubby
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Fig. 4. Outer stripe of the medulla of the kidney from the cisplatin-
treated rat 4 weeks after the third cisplatin injection. A portion of the S3
segment of the proximal convoluted tubule is lined by flat epithelial cells
(1, 2) with short, stubby microvilli (arrow), few mitochondria which
appear abnormally small, and increased ribosomal content. Compare
the microvilli of the flat epithelial cells (1, 2) with those of the
normal-appearing cell (3). Basement membrane reduplication is evident
(arrowheads). (x6500)
microvilli, decreased numbers of mitochondria which were
small, increased ribosomal and rough endoplasmic reticulum
content, and enlarged hyperchromatic nuclei (Fig. 4). Tubular
basement membranes were by and large unaltered at this stage.
Occasional mitoses were present. Inflammatory mononuclear
cells were seen rarely. Other segments of the nephron were
morphologically normal. Except for one cisplatin-treated ani-
mal at 48 hr after the third injection, cell necrosis was no longer
seen in cisplatin-treated rats at 48 hr, 1 week, and 4 weeks after
the third cisplatin injection. The changes were mainly those of
regeneration of S3 segments in the outer stripe. These changes
were characterized by the presence of flattened cells lining a
variable number of proximal tubules in this region. These cells
were ultrastructurally very similar to those described above.
Tubular basement membranes adjacent to these cells were
variably thickened and reduplicated (Fig. 4). Inflammatory cells
were seen rarely. Although mitotic activity was present, it was
relatively inconspicuous.
Discussion
In this rat model of cisplatin-induced hypomagnesemia, there
is clear evidence of renal magnesium wasting. Despite a persis-
tently lower plasma magnesium concentration and evidence of
magnesium deficiency, cisplatin-treated animals excreted the
same amount of magnesium in the urine as control animals.
Thus, these animals exhibit renal magnesium wasting since, in
humans and in experimental animals, hypomagnesemia is oth-
erwise associated with renal magnesium conservation [13—151.
A significantly higher renal excretion of magnesium in cisplatin-
treated rats during MgCl2 infusion, despite a similar elevation of
plasma magnesium concentration during MgC12 infusion (Table
4, Fig. 1) also suggests the presence of renal magnesium
wasting. Although the degree of hypomagnesemia in this model
was modest, it was associated with a significant decrease in
bone magnesium content, indicating depletion of the magne-
sium storage pool.
Clearance and micropuncture studies during the seventh and
eighth week suggested a normal transport of sodium, magne-
sium, and calcium in the superficial nephrons. The absence of
detectable tubule defect could be related to tubular adaptation
after 7 weeks of cisplatin treatment, which resulted in obscuring
the defect in magnesium reabsorption. However, urinary mag-
nesium and calcium excretion increased abnormally during
MgCl2 infusion (Table 4, Fig. 1). On the other hand, histological
studies in the cisplatin-treated rat demonstrated lesions mainly
in the S3 segment of the proximal tubules of deep nephrons. It
seems unlikely that a functional defect confined to this site
could explain entirely the defect in magnesium excretion, since
in vivo perfusion studies indicate that the thick ascending limb
of Henle's loop has a remarkable capacity to increase the
absolute reabsorption of magnesium with an increase in deliv-
ered load [16]. However, it is possible that the contribution of
S3 to magnesium reabsorption in the deep nephrons is greater
than in superficial nephrons, and the ability of the thick ascend-
ing limb of Henle's loop to increase its reabsorption (to offset a
more proximal defect) may be less than in the superficial
nephrons. Alternatively, it may be postulated that cisplatin may
cause a functional defect of magnesium transport in the thick
ascending limb of Henle's loop of the deep nephrons without
any detectable morphological changes. This may or may not be
associated with a functional defect in the S3 segment of the
proximal tubules. Finally, the abnormal renal magnesium trans-
port may be located at the more distal convoluted tubule and
collecting duct, which are not accessible to micropuncture
studies. The exact nephron sites and mechanisms responsible
for the abnormal renal magnesium handling in this animal model
are still unknown and need further investigation.
The abnormally increased renal calcium excretion during
MgC12 infusion in this rat model deserves comment. It is well
known that the infusion of either magnesium or calcium salts is
followed by an increase in the urinary excretion of magnesium,
calcium, and sodium, which may result from an interaction in
the thick ascending limb of Henle's loop [16—19]. Accordingly,
the higher urinary excretion of both magnesium and calcium
during MgC12 infusion in cisplatin-treated rats than in normal
rats suggests that cisplatin may interfere with the transport of
both cations in the thick ascending limb of Henle's loop.
Bone and muscle analysis in our present studies indicated a
decrease in magnesium, potassium, and phosphorus content in
the bone and a decrease in phosphorus content in the muscle,
whereas bone calcium content and muscle calcium, magnesium,
and potassium content were normal. These findings indicate
that magnesium depletion is present in this animal model
despite a relatively modest decrease in plasma magnesium
concentration, and further suggest that a change in bone mag-
nesium may be a good indicator of a magnesium-deficient state.
Since 95% of total body potassium is located in the skeletal
muscle, the finding of normal potassium content in the muscle
of this animal model indicates the absence of potassium deple-
tion. As the degree of magnesium deficiency in this animal
model is relatively modest, it is not surprising that potassium
deficiency may not be evident. The mechanisms that led to a
decrease in bone and muscle phosphorus content in this model
•_el— -
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are unclear. They may be due to magnesium depletion in this
animal model or to a direct effect of cisplatin.
In summary, these studies have shown that cisplatin induces
an alteration in magnesium homeostasis in the rat.
Hypomagnesemia is associated with significantly depressed
body stores of magnesium and phosphorus. These findings may
be relevant to the cisplatin-treated patient with chronic asymp-
tomatic hypomagnesemia. The exact mechanism of renal mag-
nesium wasting and the site of this defect requires further
studies (for example, micropuncture of the deep nephron). The
extrarenal factors that influence magnesium, calcium, and phos-
phorus metabolism (specifically, PTH, vitamin D, aldosterone
and so forth) in this animal model are also unknown and need
further investigation.
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